The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine
Abstract
PURPOSE: This phase II pilot study determined the efficacy and safety of alemtuzumab (Campath-1H; Burroughs Wellcome, United Kingdom) in patients with chronic lymphocytic leukemia (CLL), all of whom had previously received fludarabine and other chemotherapy regimens. PATIENTS AND METHODS: Twenty-four patients were treated with intravenous alemtuzumab at six centers in the United States. The target dose of 30 mg over 2 hours, three times weekly, was administered for up to 16 weeks. Responses were evaluated by an independent panel of experts using 1996 National Cancer Institute–sponsored Working Group criteria. Safety assessments included analysis of lymphocyte subpopulations. Antimicrobial prophylaxis was not mandatory. RESULTS: Eight patients (33%) achieved a major response (all partial remissions), with a median time to response of 3.9 months (range, 1.6 to 5.3 months). The median duration of response was 15.4 months (range, 4.6 to ≥ 38.0 months), the median time to disease progression was 19.6 months (range, 7.7 to ≥ 42.0 months), and the median survival time was 35.8 months (range, 8.8 to ≥ 47.1 months). Acute infusion-related events, mainly grades 1 and 2, were most common and most severe in the first week. Ten patients (eight nonresponders and two responders) experienced major infections on-study. Pneumocystis carinii pneumonia was reported in two patients on-study; neither had received prophylaxis. Median CD4+ and CD8+ counts decreased and then began to increase by the end of the study, with further recovery by 1-month follow-up. One of 53 samples obtained from 10 patients had a low titer of alemtuzumab antibodies. CONCLUSION: Alemtuzumab has significant activity in poor-prognosis, fludarabine-treated CLL patients. However, because of a relatively high incidence of opportunistic infections accompanying profound lymphopenia, future protocols should include mandatory prophylaxis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B., Bennett, J., Grever, M., Kay, N., Keating, M., O'Brien, S., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,819
Self-citationReshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Keating, M. J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3554 · Cited by 948
Self-citationGehan, E. A. (1961) · Journal of Chronic Diseases · doi:10.1016/0021-9681(61)90060-1 · Cited by 667
Osterborg, A., Dyer, M. J., Bunjes, D., Pangalis, G. A., Bastion, Y., Catovsky, D., & Mellstedt, H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1567 · Cited by 512
Effect of Campath-1H antibody on human hematopoietic progenitors in vitro
Gilleece, M., & Dexter, T. (1993) · Blood · doi:10.1182/blood.v82.3.807.807 · Cited by 217
Bowen, A., Zomas, A., Emmett, E., Matutes, E., Dyer, M. J. S., & Catovsky, D. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.d01-2061.x · Cited by 129
Dyer, M. J. S., Hale, G., Marcus, R. E., & Waldmann, H. (1990) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199009053522 · Cited by 71
Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period
Pangalis, G. A., Dimopoulou, M., Angelopoulou, M., et al. (2000) · Medical Oncology · doi:10.1007/bf02826220 · Cited by 13
Cited by
Moreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S. M. B., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.021 · Cited by 419
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Hallek, M. (2017) · American Journal of Hematology · doi:10.1002/ajh.24826 · Cited by 282
Infectious Complications of Chronic Lymphocytic Leukemia
WADHWA, P., & MORRISON, V (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.12.013 · Cited by 276
Han, Y., Jia, Q., Jahani, P. S., Hurrell, B. P., Pan, C., Huang, P., Gukasyan, J., Woodward, N. C., Eskin, E., Gilliland, F. D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15649-3 · Cited by 222
Lundin, J., Porwit-MacDonald, A., Rossmann, E. D., Karlsson, C., Edman, P., Rezvany, M. R., Kimby, E., Österborg, A., & Mellstedt, H. (2004) · Leukemia · doi:10.1038/sj.leu.2403258 · Cited by 118
Metadata
- Authors
- Rai, K. R., Freter, C. E., Mercier, R. J., Cooper, M. R., Mitchell, B. S., Stadtmauer, E. A., Santábarbara, P., Wacker, B., & Brettman, L.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-09-15
- Volume
- 20
- Issue
- 18
- Pages
- 3891-3897
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2019274594
- Cited by
- 307
- References
- 9
- FWCI
- 14.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine. https://app.cochat.ai/papers/10.1200/jco.2002.06.119
- The paper
- Rai, K. R., Freter, C. E., Mercier, R. J., Cooper, M. R., Mitchell, B. S., Stadtmauer, E. A., Santábarbara, P., Wacker, B., & Brettman, L. (2002). Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2002.06.119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.